share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer ALTSHULER DAVID

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer ALTSHULER DAVID

福泰制药 | 4：持股变动声明-高管 ALTSHULER DAVID
美股sec公告 ·  05/18 04:28
牛牛AI助手已提取核心信息
David Altshuler, EVP and Chief Scientific Officer at Vertex Pharmaceuticals Inc. (VRTX), completed a sale of company stock on May 15, 2024. The transaction involved the disposal of 54 shares of common stock at a price of $430.93 per share, resulting in a total sale value of $23,270.22. Following the sale, Altshuler's direct holdings in Vertex Pharmaceuticals amount to 25,813 shares. The sale was conducted in the open market and is part of the normal course of investment management for the reporting individual.
David Altshuler, EVP and Chief Scientific Officer at Vertex Pharmaceuticals Inc. (VRTX), completed a sale of company stock on May 15, 2024. The transaction involved the disposal of 54 shares of common stock at a price of $430.93 per share, resulting in a total sale value of $23,270.22. Following the sale, Altshuler's direct holdings in Vertex Pharmaceuticals amount to 25,813 shares. The sale was conducted in the open market and is part of the normal course of investment management for the reporting individual.
Vertex Pharmicals Inc.（VRTX）执行副总裁兼首席科学官大卫·阿尔舒勒于2024年5月15日完成了公司股票的出售。该交易涉及以每股430.93美元的价格出售54股普通股，总销售价值为23,270.22美元。出售后，Altshuler在Vertex Pharmicals的直接持股量为25,813股。此次出售是在公开市场上进行的，是申报人正常投资管理过程的一部分。
Vertex Pharmicals Inc.（VRTX）执行副总裁兼首席科学官大卫·阿尔舒勒于2024年5月15日完成了公司股票的出售。该交易涉及以每股430.93美元的价格出售54股普通股，总销售价值为23,270.22美元。出售后，Altshuler在Vertex Pharmicals的直接持股量为25,813股。此次出售是在公开市场上进行的，是申报人正常投资管理过程的一部分。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成，只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。